miDiagnostics is developing a molecular diagnostics pipeline, using its ultra-fast PCR technology for the detection of SARS-CoV-2, with menu expansion possibilities towards other respiratory indications, sexual transmitted diseases and any other molecular test that could merit the benefits of decentralization, diagnostic accuracy, and ease of use.
Molecular Diagnostic
miDiagnostics is developing a molecular diagnostics pipeline, using its ultra-fast PCR technology for the detection of SARS-CoV-2, with menu expansion possibilities towards other respiratory indications, sexual transmitted diseases and many others.
The miDiagnostics’ COVID-19 PCR Test is now available for use by lab professionals. Its optimized workflow, compact design, and ultra-fast and reliable results make it optimally suited for use in a decentralized testing approach.
Ultra-fast.
Ultra-reliable.
Our COVID-19 PCR test combines the convenience and speed of an antigen test with the sensitivity of a Polymerase Chain Reaction (PCR) test.
“miDiagnostics has the potential to disrupt and transform the industry by making diagnostic information available to clinician and patient alike.”
“Its easy-to-use and cost-efficient test will revolutionize point-of-care testing by directly engaging with patients and enabling speedy intervention.”
“Proud to be leading a top team and together with our numerous partners to make a significant contribution to healthcare in general.”
“As a Non-Executive Director on miDiagnostics’ Board, I have been privileged to witness its continued development. I am very proud to see many years of hard work coming to fruition and providing value, facilitating the return to a normal way of life, with potential to move high quality testing closer to the patient.”
“This technology could aid the management of outbreaks in challenging settings, such as nursing homes and home care environments, allowing healthcare professionals to adjust their management decisions at the point of care. ”
